6758
S. H. Kim et al. / Bioorg. Med. Chem. 14 (2006) 6752–6758
3. Chen, Z. X.; Xue, Y. Q.; Zhang, R.; Tao, R. F.; Xia, X.
M.; Li, C.; Wang, W.; Zu, W. Y.; Yao, X. Z.; Ling, B. J.
Blood 1991, 78, 1413.
4. Frankel, S. R.; Eardley, A.; Lauwers, G.; Weiss, M.;
Warrell, R. P., Jr. Ann. Intern. Med. 1992, 17, 292.
5. (a) Liu, X. M.; Wang, L. G.; Li, H. Y.; Ji, X. J. Biochem.
Pharmacol. 1996, 51, 1545; (b) Eisenbrand, G.; Hippe, F.;
Jakobs, S.; Muehlbeyer, S. J. Cancer Res. Clin. Oncol.
2004, 130, 627.
a cytospin centrifuge. The slides were fixed with metha-
nol and dried. The slides were then stained with Giemsa
staining solution for 20 min, rinsed in deionized water,
air-dried, and observed under a microscope equipped
with a camera. The stained cells were evaluated with re-
gard to size, cell margin regularity, and nuclear morpho-
logical characteristics.
4.6. Immunofluorescent staining and cytofluorometric
measurements
6. (a) Hoessel, R.; Leclerc, S.; Endicott, J. A.; Nobel, M.
E.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.;
Marie, D.; Marko, D.; Niederberger, E.; Tang, W.;
Eisenbrand, G.; Meijer, L. Nat. Cell Biol. 1999, 1, 60;
(b) Marko, D.; Schatzle, S.; Friedel, A.; Genzlinger, A.;
Zankl, H.; Meijer, L.; Eisenbrand, G. Br. J. Cancer
2001, 84, 283.
7. (a) Davies, T. G.; Tunnah, P.; Meijer, L.; Marko, D.;
Eisenbrand, G.; Endicott, J. A.; Noble, M. E. Structure
2001, 9, 389; (b) Knockaert, M.; Greengard, P.; Meijer, L.
Trends Pharmacol. Sci. 2002, 23, 417.
8. Tanaka, H.; Abe, E.; Miyaura, C.; Shiina, Y.; Suda, T.
Biochem. Biophy. Res. Commun. 1983, 117, 86.
9. Moon, M. J.; Lee, S. K.; Lee, J. W.; Song, W. K.; Kim, S.
W.; Kim, J. I.; Cho, C.; Choi, S. J.; Kim, Y. C. Bioorg.
Med. Chem. 2006, 14, 237.
10. Kansas, G. S.; Muirhead, M. J.; Dailey, M. O. Blood 1990,
76, 2483.
11. Wright, S. D.; Ramos, R. A.; Tobias, P. S.; Ulevitch, R. J.;
Mathison, J. C. Science 1990, 249, 1431.
12. (a) Pan, Q.; Granger, J.; O’Connell, T. D.; Somerman, M.
J.; Simpson, R. U. Biochem. Pharmacol. 1997, 54, 909; (b)
Song, X.; Bishop, J. E.; Okamura, W. H.; Norman, A. W.
Endocrinology 1998, 139, 457; (c) Hmama, Z.; Nandan,
D.; Sly, L.; Knutson, K. L.; Herrera-Velit, P.; Reiner, N.
E. J. Exp. Med. 1999, 190, 1583.
Quantitative immunofluorescence measurements were
conducted using an Epic XL flow cytofluorograph
equipped with a multiparameter data acquisition and
display system, as described previously.19 In brief, sin-
gle-cell suspensions were collected from the various cul-
tures and washed twice in ice-cold phosphate-buffered
saline (PBS, pH 7.4). Afterwards, phycoerythrin (PE)-
conjugated anti-human CD11b or fluorescein isothiocy-
anate (FITC)-conjugated anti-human CD14 monoclonal
antibodies (Becton Dickinson, San Jose, CA, USA) were
added, followed by 1 h of incubation at 4 ꢁC. After incu-
bation, the cells were washed with PBS and fixed in PBS
containing 1% paraformaldehyde, and cytofluorometric
analysis was conducted. Background staining was per-
formed via the staining of the cells with PE- or FITC-
conjugated isotype control monoclonal antibodies.
One-parameter fluorescence histograms were generated
via the analysis of at least 1· 104 cells.
4.7. Statistical analysis
13. (a) Wang, S. Y.; Chen, L. Y.; Wang, S. J.; Lin, C. K.; Ho,
C. K. Exp. Hematol. 1991, 19, 1025; (b) Makishima, M.;
Kanatani, Y.; Yamamoto-Yamaguchi, Y.; Honma, Y.
Blood 1996, 87, 3384; (c) Kang, S. N.; Chung, S. W.; Kim,
T. S. Eur. J. Pharmacol. 2001, 420, 83; (d) Kang, S. N.;
Lee, M. H.; Kim, K. M.; Cho, D.; Kim, T. S. Biochem.
Pharmacol. 2001, 61, 1487.
Student’s t-test and one-way analysis of variance (ANO-
VA) followed by the Bonferroni method were used to
determine the statistical significance of differences be-
tween the values of various experimental and control
groups. A P value of <0.05 was considered to be
significant.
14. (a) Breitman, T. R.; He, R. Y. Cancer Res. 1990, 50, 6268;
(b) Noguchi, T.; Shinji, C.; Kobayashi, H.; Makishima,
M.; Miyachi, H.; Hashimoto, Y. Biol. Pharm. Bull. 2005,
28, 563.
Acknowledgments
15. (a) Norman, A. W.; Okamura, W. H.; Hammond, M.
W.; Bishop, J. E.; Dormanen, M. C.; Bouillon, R.; van
Baelen, H.; Ridall, A. L.; Daane, E.; Khoury, R.;
Farach-Carson, M. C. Mol. Endocrinol. 1997, 11, 1518;
(b) Zanello, L. P.; Norman, A. W. J. Biol. Chem. 1997,
272, 22617; (c) Haussler, M. R.; Whitfield, G. K.;
Haussler, C. A.; Hsieh, J. C.; Thompson, P. D.; Selznick,
S. H.; Dominguez, C. E.; Jurutka, P. W. J. Bone Miner.
Res. 1998, 13, 325.
This study was supported by Grants of the Korea
Health 21 R&D Project, Ministry of Health and Wel-
fare, Republic of Korea (01-PJ10-PG6-01GN16-0005),
and the Seoul Research and Business Program (10582)
to Prof. T. S. Kim, and also by a grant of the Korea
Health 21 R&D Project, Ministry of Health and Wel-
fare, Republic of Korea, to Prof. Y.-C. Kim (A040042).
16. Kragballe, K. J. Cell. Biochem. 1992, 49, 46.
17. Warrell, R. P., Jr.; Frankel, S. R.; Miller, W. H., Jr.;
Scheinberg, D. A.; Itri, L. M.; Hittelman, W. N.; Vyas, R.;
Andreeff, M.; Tafuri, A.; Jakubowski, A., et al. N. Eng. J.
Med. 1991, 324, 1385.
18. Collins, S. J.; Ruscetti, F. W.; Gallagher, R. E.; Gallo,
R. C. J. Exp. Med. 1979, 149, 969.
19. Kim, T. S.; Kang, B. Y.; Lee, M. H.; Choe, Y. K.; Hwang,
S. Y. Br. J. Pharmacol. 2001, 134, 571.
References and notes
1. Beere, H. M.; Hickman, J. A. Anti-Cancer Drug Des. 1993,
8, 299.
2. (a) Breitman, T. R.; Selonick, S. E.; Collins, S. J. Proc.
Natl. Acad. Sci. U.S.A. 1980, 77, 2936; (b) Chomienne, C.;
Balitrand, N.; Cost, H.; Degos, L.; Abita, JP. Leuk. Res.
1986, 10, 1301.